The intracardiac electrograms were filtered at a band pass of 30-400 Hz, and recorded using an EPLab (Quinton, Seattle, WA, USA). Each pacing stimulus was performed at twice the diastolic threshold with a programmable stimulator (Model 3F-61: NEC San-ei, Tokyo, Japan). The RF current was delivered between the distal tip electrode of the ablation catheter (EP Technologies) and a cutaneous indifferent adhesive pad attached to the left posterior side of the thorax with a target temperature of 55-60°C.
In the control group, we introduced 3 or 4 sheaths through the right and left femoral veins. We also introduced a 5F sheath into the left femoral artery to record the arterial blood pressure in 5 of the control group. Intracardiac catheters were introduced into the high right atrium, right ventricle and His bundle positions. An additional catheter was positioned in the coronary sinus in some of the patients. All sheaths were removed immediately after the session was completed in both groups.
Blood Sample Collection and Analysis
Blood samples were collected at 7 different times in each patient. Baseline samples were drawn before introducing the sheaths. The next sampling was performed at 5 min after the last RF current delivery (during the procedure). After the session, additional blood samples were taken at 30 min, 6 h and 24 h after removal of the sheaths, then at 3 and 6 days after the session. All samples were drawn by cubital vein puncture with a minimum of venous stasis, except for when obtained during the procedure, in which case blood was then drawn through the sheath located in the femoral vein. Care was taken to avoid activation of platelets while drawing the blood samples.
In the last 20 of the 43 patients who had ablation therapy, we measured the serum HGF concentration at baseline, and at 6 and 24 h, and 3 and 6 days after the procedure. We did not measure the HGF concentration during the procedure or 30 min after the removal of the sheaths because of possible effects from the administration of heparin. 15 In the control group, the blood samples were collected at 4 different times: at baseline, and 24 h, 3 and 6 days after the procedure. Because the focus was on the existence of a delayed phase of thrombogenesis, we did not obtain samples during the procedure. All samples were drawn by cubital vein puncture with a minimum of venous stasis.
The serum and citrated plasma were obtained from venous blood by centrifugation at 3,000 rpm for 15 min at 4°C. The thrombin -antithrombin III complex (TAT) was measured by enzyme immunoassay, and HGF by enzymelinked immunosorbent assay using commercial reagents (SRL, Tokyo, Japan). The upper reference limits were TAT <3.0 ng/ml and HGF <0.40 ng/ml.
Follow-up and Anticoagulation Regimen
All the patients in the ablation group received anticoagulation with heparin after the diagnostic EPS and prior to the RF applications (5,000 U by bolus injection, followed by 1,000 U/h during the rest of the procedure). Antiplatelet therapy with 81 mg of aspirin orally was begun immediately after the procedure and continued for 1 month. None of the control patients were treated with heparin or aspirin.
Statistical Analysis
All data are presented as mean ± SD. Comparisons between the groups of patients were performed with the unpaired Student's t test. Multiple comparisons were examined by one factor analysis of variance with Bonferroni's method to adjust the p value. Simple regression analysis was used to estimate the correlation between 2 parameters. p<0.05 was considered statistically significant.
Results

RF-CA
All patients were successfully treated by RF-CA without any adverse effects. A sudden impedance rise was seen during the delivery of the RF energy in 3 of the 43 patients, but there no cases of visible clotting at the tip of the ablation catheter. No clinical thromboembolic complications occurred in either of the study groups during the procedure or the follow-up period (median: 14 months, range: 6-21 months).
The demographic data are presented in Table 1 . There were no significant differences in terms of age, gender, systolic and diastolic blood pressure, or the number of catheters between the ablation and EPS groups.
Serial Change in TAT
The serial change in plasma TAT concentration is shown in Fig 1. In the ablation group, the baseline concentration was 2.8±1.6 ng/ml, 42.8±15.5 ng/ml during the procedure, and 13.0±7.8 ng/ml at 30 min, 5.6±2.3 ng/ml at 6 h, 10.0± 10.0 ng/ml at 24 h, 21.3±19.0 ng/ml at 3 days and 11.9±16.7 ng/ml at 6 days after removal of the sheaths. The TAT concentration significantly increased during the RF-CA procedure (first peak), and then decreased to baseline by 6 h after removal of the sheaths; however, it increased again by 24 h after the session, and reached a second peak by 3 days after the RF-CA. At 6 days after the session, the TAT concentration tended to diminish, but was still significantly high compared with the baseline value. In the EPS group, the baseline plasma TAT concentration was 2.7±1.5 ng/ml, and 4.5±5.2 ng/ml at 24 h, 2.5±1.4 ng/ml at 3 days and 2.6±1.3 ng/ml at 6 days after the session. None of these values was significantly different to the baseline value. However, the difference between the 2 groups was statistically significant at 24 h and 3 and 6 days after the procedure.
The plasma TAT concentration was not significant different between right-sided and left-sided ablation. The total energy of the RF current did not correlate with either the first or second peak of TAT. In both the ablation and EPS groups, the TAT concentration was not significantly different between the patients who had the catheters introduced through the artery and the other patients.
Serial Change in HGF
In the last 20 cases of the ablation group, the serum HGF concentration was 0.22±0.07 ng/ml at baseline, 0.41±0.17 ng/ml at 6 h, 0.43±0.17 ng/ml at 24 h, 0.32±0.02 ng/ml at 3 days and 0.24±0.05 ng/ml at 6 days after the ablation procedure. There was a significant increase until 24 h after the ablation and then a gradual decline (Fig 2) to the baseline level by 3 days after the session.
Correlation Between TAT and Procedure Time Prior to Heparin Administration
The procedure time prior to the administration of heparin was compared with the first and second peaks in plasma TAT concentration. The first peak significantly correlated with the procedure time, not the second peak (Fig3). Neither the number of RF applications nor the total energy had a relationship to TAT concentration at any given time instance.
Correlation Between TAT and HGF
There was no significant correlation between plasma TAT concentration and the simultaneously obtained HGF concentration. We focused on the serum HGF concentration obtained 6 h after the procedure in relation to the first and second peak of TAT. The first peak of TAT did not have a statistically significant correlation with serum HGF concentration (r=0.346, p=0.27), but the second peak of TAT exhibited a weak but not statistically significant correlation (r=0.473, p=0.10). For further analysis, we dichotomized the patients at an HGF concentration of 0.40 ng/ml Serial change in plasma thrombin -antithrombin III complex (TAT) concentration in the groups who underwent either radiofrequency catheter ablation (square) or a diagnostic electrophysiologic study (EPS) alone (circle). The plasma TAT concentration in the ablation group clearly showed a first peak during the ablation procedure and a second peak 3 days after the procedure. The EPS group showed no statistically significant change in plasma TAT concentration. *p<0.008 vs baseline, + p<0.05 vs EPS group. measured at 6 h after the session. This value was chosen because it represented the upper normal concentration of HGF. Of the 20 patients in whom serial TAT and HGF concentrations were investigated, 5 had a serum HGF level of more than 0.40 ng/ml at 6 h after the RF ablation and they were classified as the HGF high group; the remaining 15 cases were the HGF low group. The demographic data are presented in Table 2 . There were no significant differences in age, gender, blood pressure or total energy delivery of the RF current. The HGF high group had a relatively larger number of RF applications, but this did not exhibit a statistically significant difference.
Plasma TAT concentration in the HGF high group was 4.4±3.3 ng/ml at baseline, 44.7±22.5 ng/ml during the procedure, and 10.0±7.9 ng/ml at 30 min, 7.0±3.6 ng/ml at 6 h, 11.1±7.2 ng/ml at 24 h, 44.2±20.7 ng/ml at 3 days and 18.8± 27.5 ng/ml at 6 days after the session. the corresponding values in the HGF low group were 2.5±0.6 ng/ml, 41.7±15.0 ng/ml, 11.3±7.2 ng/ml, 5.6±1.9 ng/ml, 6.5±3.2 ng/ml, 13.8± 17.8 ng/ml and 9.2±7.8 ng/ml (Fig 4) .
Both subgroups showed a first peak followed by a reduction in the plasma TAT concentration. The HGF high group exhibited the double-peaked pattern with the second peak at 3 days after the procedure, but the HGF low group did not show a significant second elevation in TAT.
Discussion
This study demonstrated that the thrombogenesis caused by RF-CA has 2 phases: an acute phase peaking during the procedure and a delayed phase peaking 3 days after the procedure. Because the EPS group did not show a second elevation in the TAT concentration, the delayed phase of thrombogenesis is caused by the RF current and not by the placement of catheters.
Thrombogenesis Caused by Radiofrequency Current
The thrombogenesis associated with RF-CA has 3 factors: hemostasis caused by the placement of the catheters, a direct heating effect triggering the platelet and coagulation system, and endothelial damage caused by the RF current.
The hemostasis that occurs with the placement of catheters has been described, 6, 7, 16, 17 with some investigators correlating it with the duration of the pre-heparin procedure, as was seen in the present study. 7 Another report showed that platelet aggregability increased during RF current delivery, 9 and Manolis et al showed that RF-CA provoked an elevation in the D-dimer concentration by 48 h after the procedure. 8 These previous studies have not fully elucidated the influence of the RF current on thrombus formation nor have they observed the delayed phase of thrombogenesis. Previous experimental studies have shown histological changes in association with RF-CA, 10, 18, 19 one of which is thrombus formation 7 days after the procedure. 10, 18 Thus, it is also unclear how long the thromboembolic risk continues after RF-CA.
To the best of our knowledge, this is the first report to clearly demonstrate the acute and delayed phase of the thrombogenesis caused by RF current application and may explain the discrepancy in the previous studies. According to our results, the elevation of the D-dimer concentration reported by Manolis et al might represent the delayed phase, but comparison of the present and previous studies depends on the anticoagulation regimen, including the administration of heparin and low molecular weight heparin. 7, 8, 17 
Endothelial Damage and Thrombogenesis
Endothelial cells are highly sensitive to injury, so selective tissue damage by ablation results in damage or loss, 10 which leads to platelet adhesion, activation, aggregation, and fibrin generation, and thus to thrombus formation at the The patients who exhibited an HGF concentration greater than 0.40 ng/ml constituted the HGF high group (circle), and the others constituted the HGF low group (square). Both the HGF-high and -low patients exhibited a first peak in the plasma TAT concentration during the procedure and a second peak 3 days after the session. The first peak in TAT concentration in both groups did not differ, but the second peak was significantly higher in the HGF high group. *p<0.008 vs baseline, + p<0.05 vs EPS group.
site of injury. Because the endothelium has a low turnover, 20 it needs a longer recovery period when the endothelium is damaged to a certain degree of size. To the best of our knowledge, few reports have focused on the damage and repair of the endothelium after RF-CA. A recent experimental report demonstrated that re-endothelialization was completed by 21 days after photochemically induced endothelial injury, 11 so we consider that the delayed phase of thrombogenesis is the result of endothelial damage. We found a correlation between the first peak in plasma TAT concentration and the procedure time prior to heparin administration, but not with the second, which supports our hypothesis that the first peak is caused by hemostasis from catheter placement and the second peak is caused by endothelial damage from the RF current. Because the thrombogenesis caused by the endocardial damage began just after the injury from the RF current, the second peak in TAT concentration might be a rebound phenomenon after cessation of the heparin administration. Thus, the anticoagulation regimen influences the magnitude and time course of the delayed phase of the thrombogenesis. We did not design a control group with subjects who underwent ablation therapy without heparin, and therefore the influence of the anticoagulation regimen was not exactly evaluated. In spite of that limitation, this study clearly showed that RF-CA is associated with a delayed phase of thrombogenesis. The total energy and number of RF current applications did not correlate with second peak in TAT concentration, because not all RF applications necessarily result in effective lesion formation, mainly because of unstable catheter position.
HGF and Endothelial Damage
HGF is an endothelium-specific growth factor and because the proliferation and cell motility involved in the repair of mechanically wounded endothelial cell monolayers is induced by HGF, 21 increased local HGF production would enhance re-endothelialization after injury from RF current application.
Studies have shown that serum HGF is a marker for endothelial damage. A recent experimental study showed that serum HGF was an early marker for arterial thrombi induced by mechanical endothelial damage, 22 and another report showed that high serum HGF concentrations might predict adverse events in cases of acute coronary syndrome. 14 In the present study, a significantly high second peak in TAT concentration was seen in the group in which the serum HGF concentration was greater than 0.40 ng/ml at 6 h after RF-CA, which suggests that the serum HGF concentration at that time may predict the degree of delayed thrombogenesis.
Thus we consider that the HGF high group had greater endothelial damage, although it was difficult to precisely evaluate it. The HGF high group included 3 cases of multiple accessory pathways and the group overall had more applications of RF current. Therefore, the HGF high group included cases that were more difficult to treat and thus evoked greater endothelial damage.
A previous study established that heparin was a potent enhancer of HGF synthesis in various types of cells 23 and administration of heparin increased the serum concentration of HGF for 1 h after the infusion, an effect that disappeared 3 h later. 15 We measured the serum HGF concentration at least 6 h after the infusion of heparin, so the influence of the heparin would have been completely diminished.
Study Limitations
This study has the principle limitation that the elevation of the biochemical markers did not directly correlate with the clinical thromboembolic risk. No clinical thromboembolic event was seen in this study. In addition, we could not directly correlate the endothelial damage and thrombus formation with the pathological examination.
The second peak in TAT concentration depends on the regimen of anticoagulation, and we might not have observed the precise peak of the thrombogenesis caused by the endothelial damage. However, the control group, which had an EPS but no ablation therapy, did not have an elevation in the TAT concentration in the delayed phase. Thus, we believe the delayed phase of thrombogenesis was clearly caused by the RF current itself.
As previously described, sampling through intravascular sheaths causes error, 24 but we obtained all the samples by a cubital vein puncture with minimum venous stasis, except for 1 sample obtained during the procedure.
HGF is a known pleiotropic agent acting under various conditions, and thus the serum HGF concentration might not indicate only endothelial damage. We compared the prognostic significance of serum HGF concentration in a small number of cases, but a much larger series of patients is required to determine this.
Clinical Implications
The present study indicated that subclinical thrombogenesis continued for 6 days after RF-CA and that endothelial damage might be the cause. Although we have not directly revealed the presence of clinical thromboembolism, the results indicate a possible risk of delayed thrombosis in a limited situation. Oral administration of aspirin at a dose of 81 mg did not completely prevent the delayed phase of thrombogenesis.
Conclusions
Thrombogenesis provoked by RF-CA has been considered to caused by hemostasis from the placement of the intravascular catheters, and that it disappears immediately after removal of the catheters and introducer sheaths. However, the present study clearly showed that the thrombogenesis has 2 phases: an acute phase during the procedure, and a delayed phase that peaked at 3 days after the procedure. The delayed phase of thrombogenesis is provoked by endothelial damage caused by application of the RF current.
